In Segment C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment right until illness progression or even the contributors are unable to tolerate the study drugs. Ubiquitin-related proteins that control The soundness of essential super enhancer-mediated proteins have https://carsono887cny0.wikiitemization.com/user